MBC Treatment

Posters

NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases

CAR T Cell Therapy

IBRANCE

Approved Health Canada Indications and Clinical Use for Ibrance
• In combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
• In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor  2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy. Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist.

When the Patient Is the Loser (American Insurer Article)

Memorial Sloan Kettering Cancer Center

Provides a database of herbs, botanicals and supplements

Close Menu